Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001907826 | SCV002133582 | uncertain significance | Vici syndrome | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 35 of the EPG5 gene. It does not directly change the encoded amino acid sequence of the EPG5 protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs200936655, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with EPG5-related conditions. ClinVar contains an entry for this variant (Variation ID: 1365080). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002550339 | SCV003555822 | uncertain significance | Inborn genetic diseases | 2021-04-15 | criteria provided, single submitter | clinical testing | The c.6049+4G>A intronic alteration consists of a G to A substitution 4 nucleotides after exon 35 (coding exon 35) of the EPG5 gene. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |